keyword
https://read.qxmd.com/read/38515071/long-term-multicenter-comparison-shows-equivalent-efficacy-of-monoclonal-antibodies-in-severe-asthma-therapy
#1
JOURNAL ARTICLE
Moritz Z Kayser, Hendrik Suhling, Jan Fuge, Christopher A Hinze, Nora Drick, Nikolaus Kneidinger, Jürgen Behr, Christian Taube, Tobias Welte, Ina Haasler, Katrin Milger
BACKGROUND: Monoclonal antibodies (biologics) drastically changed severe asthma therapy. Mepolizumab (anti-interleukin (IL) 5), benralizumab (anti-IL5 receptor alpha), and dupilumab (anti-IL4/13) are the most used biologics in this context. While all biologics are efficient individually, the choice of biologic is complicated by insufficient data on their comparative long-term treatment efficacy. Here, we compare the real-life efficacy of these biologics in asthma therapy over 12 months...
March 21, 2024: BMC Pulmonary Medicine
https://read.qxmd.com/read/38376154/investigating-the-impact-of-antibiotic-induced-dysbiosis-on-protection-from-clostridium-difficile-colitis-by-mouse-colonic-innate-lymphoid-cells
#2
JOURNAL ARTICLE
Md Jashim Uddin, Brandon Thompson, Jhansi L Leslie, Casey Fishman, Katia Sol-Church, Pankaj Kumar, William A Petri
Innate lymphoid cells (ILCs) play a critical role in maintaining intestinal health in homeostatic and diseased conditions. During Clostridium difficile infection (CDI), IL-33 activates ILC2 to protect from colonic damage and mortality. The function of IL-33 and ILC is tightly regulated by the intestinal microbiota. We set out to determine the impact of antibiotic-induced disruption of the microbiome on ILC function. Our goal was to understand antibiotic-induced changes in ILC function on susceptibility to C...
February 20, 2024: MBio
https://read.qxmd.com/read/38371150/the-effects-of-benralizumab-on-lung-volumes-and-airway-resistance-in-severe-eosinophilic-asthma-a-real-world-study
#3
JOURNAL ARTICLE
António Madeira Gerardo, Carolina da Silva Alves, Margarida Gomes, Cecília Pardal, Anna Sokolova, Hedi Liberato, Ana Mendes, Fernanda S Tonin, Filipa Duarte-Ramos, Carlos Lopes
INTRODUCTION: Add-on biological monoclonal antibodies such as benralizumab (anti-IL-5Ra) are recommended by international guidelines to reduce exacerbations in severe eosinophilic asthma (SEA). However, few studies have assessed the impact of these therapies on lung function-related outcomes. Our goal was to evaluate the effectiveness of benralizumab on lung function, including lung volumes and airway resistance, in SEA patients in Portugal. METHODS: This was a real-world, observational, prospective, multicentric study including adult patients diagnosed with SEA (January-June 2023)...
January 2024: Curēus
https://read.qxmd.com/read/38360807/immune-endotyping-and-gene-expression-profile-of-patients-with-chronic-rhinosinusitis-with-nasal-polyps-in-the-aspirin-exacerbated-respiratory-disease-aerd-and-the-non-aerd-subgroups
#4
JOURNAL ARTICLE
Javad Nazari, Faezeh Shahba, Negin Jafariaghdam, Saleh Mohebbi, Saba Arshi, Mohammad Hassan Bemanian, Morteza Fallahpour, Sima Shokri, Fatemeh Atashrazm, Saeed Amini, Maryam Roomiani, Mahnaz Jamee, Pegah Babaheidarian, Majid Khoshmirsafa, Mohammad Nabavi
BACKGROUND: Chronic Rhinosinusitis (CRS) is a paranasal sinus inflammatory disease and is divided into two subgroups defined as CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP). CRSwNP displays a T helper (Th)2 biased phenotype, and based on sensitivity or tolerance to aspirin or non-steroidal anti-inflammatory drugs (NSAID), is further subdivided into Aspirin-exacerbated respiratory disease (AERD) and non-AERD groups. Considering the challenge of diagnosis and treatment in patients with CRSwNP, particularly the AERD subtype, and the significance of endotyping in these patients, we examined the immune profile and endotyping based on gene expression analysis in the AERD and the non-AERD groups of patients with CRSwNP...
February 15, 2024: Allergy, Asthma, and Clinical Immunology
https://read.qxmd.com/read/38327518/features-of-severe-asthma-response-to-anti-il5-il5r-therapies-identikit-of-clinical-remission
#5
JOURNAL ARTICLE
Giovanna Elisiana Carpagnano, Andrea Portacci, Santi Nolasco, Aikaterini Detoraki, Alessandro Vatrella, Cecilia Calabrese, Corrado Pelaia, Francesca Montagnolo, Giulia Scioscia, Giuseppe Valenti, Maria D'Amato, Maria Filomena Caiaffa, Massimo Triggiani, Nicola Scichilone, Claudia Crimi
INTRODUCTION: Clinical remission (CliR) achievement has been recognized as a new potential outcome in severe asthma. Nevertheless, we still lack a detailed profile of what features could better identify patients undergoing clinical remission. In this study, we aim to address this issue, tracing a possible identikit of patients fulfilling remission criteria. METHODS: We enrolled 266 patients with severe eosinophilic asthma (SEA) treated with a 12-month course of anti-IL5/IL5 receptor (IL5r) monoclonal antibodies...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38254772/beyond-pd-l-1-blockade-in-microsatellite-instable-cancers-current-landscape-of-immune-co-inhibitory-receptor-targeting
#6
REVIEW
Edoardo Crimini, Luca Boscolo Bielo, Pier Paolo Maria Berton Giachetti, Gloria Pellizzari, Gabriele Antonarelli, Beatrice Taurelli Salimbeni, Matteo Repetto, Carmen Belli, Giuseppe Curigliano
High microsatellite instability (MSI-H) derives from genomic hypermutability due to deficient mismatch repair function. Colorectal (CRC) and endometrial cancers (EC) are the tumor types that more often present MSI-H. Anti-PD(L)-1 antibodies have been demonstrated to be agnostically effective in patients with MSI-H cancer, but 50-60% of them do not respond to single-agent treatment, highlighting the necessity of expanding their treatment opportunities. Ipilimumab (anti-CTLA4) is the only immune checkpoint inhibitor (ICI) non-targeting PD(L)-1 that has been approved so far by the FDA for MSI-H cancer, namely, CRC in combination with nivolumab...
January 9, 2024: Cancers
https://read.qxmd.com/read/38249820/biological-anti-il-5-il-5r-therapeutics-for-chronic-obstructive-pulmonary-disease-copd-with-specific-treatable-traits-a-real-world-retrospective-analysis
#7
JOURNAL ARTICLE
Forest Day de Larrañaga, Alexandre Joubert, Isabelle Drouin, Isabelle Ouellet, Pei Zhi Li, Bryan A Ross, Carolyn J Baglole, Jean Bourbeau
INTRODUCTION: We describe the use of anti-IL-5 monoclonal antibodies from a COPD clinic, a source other than traditional clinical trials. The objectives were to characterize the patient subgroup prescribed anti-IL-5 monoclonal antibodies and to report potential benefits. METHODS: This is a retrospective case series study of 17 patients treated in a COPD subspecialty clinic. All patients had a diagnosis of COPD (post-bronchodilator FEV1/FVC <0.7) and had been prescribed an anti-IL-5 biologic for at least 8 months...
2024: International Journal of Chronic Obstructive Pulmonary Disease
https://read.qxmd.com/read/38152351/domestic-parasitic-infections-in-patients-with-asthma-and-eosinophilia-in-germany-three-cases-with-learnings-in-the-era-of-anti-il5-treatments-letter
#8
COMMENT
Muhammad Ifham Hanif, Bagus Muhammad Ihsan, Mentari Maratus Sholihah
No abstract text is available yet for this article.
2023: Journal of Asthma and Allergy
https://read.qxmd.com/read/38042707/comparison-of-long-term-response-and-remission-to-omalizumab-and-anti-il-5-il-5r-using-different-criteria-in-a-real-life-cohort-of-severe-asthma-patients
#9
MULTICENTER STUDY
Marcela Valverde-Monge, Patricia Sánchez-Carrasco, Diana Betancor, Blanca Barroso, José Manuel Rodrigo-Muñoz, Ignacio Mahillo-Fernández, Ebymar Arismendi, Irina Bobolea, Blanca Cárdaba, María Jesús Cruz, Victoria Del Pozo, Javier Domínguez-Ortega, Francisco Javier González-Barcala, José María Olaguibel, Juan Alberto Luna-Porta, Carlos Martínez-Rivera, Joaquim Mullol, Xavier Muñoz, Lorena Peleteiro-Pedraza, Cesar Picado Valles, Vicente Plaza, Santiago Quirce, Manuel Jorge Rial, Lorena Soto-Retes, Antonio Valero, Joaquín Sastre
BACKGROUND: Evaluation of biologic therapy response is vital to monitor its effectiveness. Authors have proposed various response criteria including good responder, super-responder, non-responder, and clinical remission. OBJECTIVES: To ascertain the prevalence of response and clinical remission after long-term treatment (>6 months) of anti-IgE and anti-IL-5/IL-5Rα biologics, compare these results with existing criteria, and identify predictors for non-responders and clinical remission...
January 2024: Archivos de Bronconeumología
https://read.qxmd.com/read/38004305/biologics-for-chronic-rhinosinusitis-a-modern-option-for-therapy
#10
REVIEW
Romica Cergan, Ovidiu Nicolae Berghi, Mihai Dumitru, Daniela Vrinceanu, Felicia Manole, Crenguta Sorina Serboiu
Chronic rhinosinusitis (CRS) is an important ENT pathology which affects about 5-12% of the general population. The treatment of CRS can be pharmacological (nasal sprays, douches, systemic antibiotics and steroids), surgical (endoscopic sinus surgery) or immunological according to established algorithms. CRS was divided for many years into CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP). New ways of classifying CRS by endotypes (presence of neutrophilia, eosinophilia, fibrosis, glandular hypertrophy and epithelial dysmorphisms) appeared after the most recent understandings of the pathophysiology of the disease...
November 5, 2023: Life
https://read.qxmd.com/read/37972921/efficacy-and-safety-of-biologics-for-oral-corticosteroid-dependent-asthma-a-systematic-review-and-network-meta-analysis
#11
JOURNAL ARTICLE
Phichayut Phinyo, Thanachit Krikeerati, Irin Vichara-Anont, Torpong Thongngarm
BACKGROUND: A maintenance oral corticosteroid (OCS) in addition to high-dose inhaled corticosteroids plus long-acting β2 -agonists in patients with severe asthma leads to long-term adverse events. Oral corticosteroid-sparing agents are of high priority. OBJECTIVE: This network meta-analysis assessed biologics' comparative efficacy and safety in OCS-dependent patients with asthma. METHODS: We performed a systematic search through PubMed, Scopus, Embase, the Cochrane Center of Controlled Trials, and Google Scholar for randomized controlled trials that addressed the efficacy and safety of biologics compared with placebo in OCS-dependent patients with asthma from inception to July 2023...
February 2024: Journal of Allergy and Clinical Immunology in Practice
https://read.qxmd.com/read/37965273/domestic-parasitic-infections-in-patients-with-asthma-and-eosinophilia-in-germany-three-cases-with-learnings-in-the-era-of-anti-il5-treatments
#12
JOURNAL ARTICLE
Michaela Barnikel, Ulrich Grabmaier, Pontus Mertsch, Felix Ceelen, Christian Janke, Jürgen Behr, Nikolaus Kneidinger, Katrin Milger
Eosinophilic inflammation is a hallmark of asthma, and blood eosinophilia has been established as a biomarker for phenotyping asthma and predicting the response to anti-IL5 treatments. Although parasitic infections are rare in European adults, they remain an important differential diagnosis for blood eosinophilia. We present three patients with both domestic parasitic infections and asthma to raise awareness of the potential challenge of eosinophilia and to provide experience in the management of parasitic infections in the setting of planned or ongoing anti-IL5 treatment...
2023: Journal of Asthma and Allergy
https://read.qxmd.com/read/37933940/-control-de-asma-grave-predominantemente-eosinof%C3%A3-lica-con-el-uso-de-anti-il-5
#13
JOURNAL ARTICLE
Martha Alicia Ruiz-Peñaloza, José Jesús López-Tiro, Zayra Estefania Ortíz-Monteón, Carolina García-Rosas
BACKGROUND: Asthma is a chronic inflammatory disease of the airways, caused by inflammatory cells and mediators, associated with smooth muscle dysfunction, causing variable airflow obstruction. With high, low and mixed type 2 immunoinflammatory mechanisms (endotypes). Severe asthma is that which requires step 4 or 5 of treatment (GINA 2023). The TH2 High phenotype, non-allergic with eosinophilia and FENO, is the second most common. It affects 300 million people around the world. OBJETIVE: Describe asthma biomarkers after the use of antiinterleukin 5, Benralizumab, in adults with severe asthma...
September 2023: Revista Alergia Mexico: Organo Oficial de la Sociedad Mexicana de Alergia e Inmunología, A.C
https://read.qxmd.com/read/37658954/developments-in-the-management-of-severe-asthma-in-children-and-adolescents-focus-on-dupilumab-and-tezepelumab
#14
REVIEW
Yoni E van Dijk, Niels W Rutjes, Korneliusz Golebski, Havva Şahin, Simone Hashimoto, Anke-Hilse Maitland-van der Zee, Susanne J H Vijverberg
Severe asthma in children and adolescents exerts a substantial health, financial, and societal burden. Severe asthma is a heterogeneous condition with multiple clinical phenotypes and underlying inflammatory patterns that might be different in individual patients. Various add-on treatments have been developed to treat severe asthma, including monoclonal antibodies (biologics) targeting inflammatory mediators. Biologics that are currently approved to treat children (≥ 6 years of age) or adolescents (≥ 12 years of age) with severe asthma include: anti-immunoglobulin E (omalizumab), anti-interleukin (IL)-5 (mepolizumab), anti-IL5 receptor (benralizumab), anti-IL4/IL13 receptor (dupilumab), and antithymic stromal lymphopoietin (TSLP) (tezepelumab)...
September 2, 2023: Paediatric Drugs
https://read.qxmd.com/read/37654647/anti-il5-monoclonal-antibodies-reduce-asthma-exacerbations-and-corticosteroids-dose-in-three-eosinophilic-granulomatosis-with-polyangiitis-case-reports
#15
JOURNAL ARTICLE
Elpida Skouvaklidou, Maria Kipourou, Dimitrios Zisopoulos, Periklis Vounotrypidis, Konstantinos Katsoulis
Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare multisystem necrotizing small and medium-sized vessel vasculitis with eosinophilic adult-onset asthma as part of its spectrum. Therapeutic choices include corticosteroids, immunosuppressive agents, and novel immunomodulators. Mepolizumab and benralizumab are monoclonal antibodies targeting Interleukin-5 (IL-5), which plays a leading role in every stage of production and maturation of eosinophils and are recently undergoing evaluation and administered in steroid-dependent, relapsing and/or refractory EGPA...
June 2023: Mediterranean journal of rheumatology
https://read.qxmd.com/read/37651801/the-effect-of-anti-il5-monoclonal-antibodies-on-regulatory-and-effector-t-cells-in-severe-eosinophilic-asthma
#16
JOURNAL ARTICLE
Laura Bergantini, Tommaso Pianigiani, Miriana d'Alessandro, Sara Gangi, Behar Cekorja, Elena Bargagli, Paolo Cameli
INTRODUCTION: Biological treatments have redesigned the clinical management of severe eosinophilic asthmatic (SA) patients. Despite emerging evidence supporting the role of natural Killer (NK), and T regulatory cells (Treg) in the pathogenesis of asthma, no data is available on the effects of anti-IL5/IL5R therapies on these cell subsets. METHODS: We prospectively enrolled fourteen SA patients treated with benralizumab (n = 7) or mepolizumab (n = 7) and compared them with healthy controls (HC) (n = 11) and mild to moderate asthmatic (MM) patients (n = 9)...
August 29, 2023: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/37467753/long-term-use-of-mepolizumab-in-a-case-of-chronic-eosinophilic-pneumonia-extending-interval-dosing
#17
JOURNAL ARTICLE
Alicia Prieto-García, María Isabel Peligros, Isabel Pérez Tamayo, José Manuel Zubeldia, Luis Álvarez-Sala, Cristina Lavilla
Introduction Mepolizumab, a humanized anti IL-5 monoclonal antibody, has been used off-label for chronic eosinophilic pneumonia (CEP), inducing disease remission and saving systemic corticosteroids. Case Study: We present a case of CEP, requiring long-term corticosteroids therapy due to relapse upon withdrawal. Mepolizumab was started and maintained for 2 years and 6 months. Results: Corticosteroids could be withdrawn and mepolizumab dose interval was spared up to 10 weeks with no disease relapse. Conclusion: Mepolizumab is shown to be useful for chronic eosinophilic pneumonia, allowing corticosteroid withdrawal...
July 19, 2023: Journal of Asthma
https://read.qxmd.com/read/37422794/inhibition-of-creb-promotes-glucocorticoids-action-on-airway-inflammation-in-pediatric-asthma-by-promoting-ferroptosis-of-eosinophils
#18
JOURNAL ARTICLE
Tong Yu, Yiping Yu, Yingyu Ma, Guoqing Chen
BACKGROUND: Pediatric asthma is a common chronic disease of childhood with airway inflammation. Cyclic adenosine monophosphate response element binding protein (CREB) plays a significant role in the transcription of proinflammatory genes, but its role in pediatric asthma has remained unclear. Herein, we investigated the functions of CREB in pediatric asthma. METHODS: Eosinophils were purified from the peripheral blood of interleukin 5 (IL5) transgenic (IL5T) neonatal mice...
2023: Allergologia et Immunopathologia
https://read.qxmd.com/read/37407419/advances-in-the-maintenance-of-anca-vasculitis-remission
#19
REVIEW
Loïc Guillevin
The maintenance treatment of ANCA-associated vasculitides (AAVs) has benefited from the results of several prospective clinical trials focusing on the evaluation of new drugs, therapeutic strategies, and adjuvant treatments. They also showed that rituximab was the most effective agent to maintain remission. However, because treatments can induce adverse events, including facilitating infections, therapeutic strategies should be adapted to find the optimal dose(s) and their administration duration(s) and to make them commensurate to the expected severity of relapse...
July 3, 2023: Best Practice & Research. Clinical Rheumatology
https://read.qxmd.com/read/37295671/real-world-effectiveness-of-interleukin-5-5ra-targeted-biologics-in-severe-eosinophilic-asthma-with-comorbid-bronchiectasis
#20
JOURNAL ARTICLE
Sarah A Bendien, Hans A Kroes, Lotte Hg van Hal, Gert-Jan Braunstahl, Marielle Eac Broeders, Karen Tm Oud, Kornelis Wiebe Patberg, Frank Wjm Smeenk, Ilonka Hpaa van Veen, Els Jm Weersink, Karin B Fieten, Simone Hashimoto, Anneke van Veen, Jaap K Sont, Astrid van Huisstede, Marjo Jt van de Ven, Bas Langeveld, Anke-Hilse Maitland-van der Zee, Anneke Ten Brinke
BACKGROUND: Bronchiectasis is a common co-morbidity in patients with asthma and associated with increased disease severity. In patients with severe eosinophilic asthma biologics targeting interleukin (IL)-5/5Ra have shown beneficial effects on oral corticosteroid (OCS) use and exacerbation frequency. However, how coexisting bronchiectasis affects the response to these treatments is unknown. OBJECTIVE: To evaluate the real-world effectiveness of anti-IL-5/5Ra therapy in patients with severe eosinophilic asthma and comorbid bronchiectasis on exacerbation frequency and daily maintenance and cumulative OCS dose...
June 7, 2023: Journal of Allergy and Clinical Immunology in Practice
keyword
keyword
99381
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.